RT Journal Article
SR Electronic
T1 Association of nocebo hyperalgesia and basic somatosensory characteristics in a large cohort
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.08.20190728
DO 10.1101/2020.09.08.20190728
A1 Mari Hanna Feldhaus
A1 Björn Horing
A1 Christian Sprenger
A1 Christian Büchel
YR 2020
UL http://medrxiv.org/content/early/2020/09/10/2020.09.08.20190728.abstract
AB Medical outcomes are strongly affected by placebo and nocebo effects. Prediction of who responds to such expectation effects has proven to be challenging. Most recent approaches to prediction have focused on placebo effects in the context of previous treatment experiences and expectancies, or personality traits. However, a recent model has suggested that basic somatosensory characteristics play an important role in expectation responses. Consequently, this study investigated not only the role of psychological variables, but also of basic somatosensory characteristics. In this study, 624 participants underwent a placebo and nocebo heat pain paradigm. Additionally, individual psychological and somatosensory characteristics were assessed. While no significant correlations for placebo responses were identified, nocebo responses were correlated with personality traits (e.g. neuroticism) and somatosensory characteristics (e.g. thermal pain threshold). Importantly, the correlations between somatosensory characteristics and nocebo responses were among the strongest. This study shows that apart from personality traits, basic somatosensory characteristics play an important role in individual nocebo responses, in agreement with the novel idea that nocebo responses result from the integration of top-down expectation and bottom-up sensory information.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialWe would like to mention, that our study is post-registered at the DRKS (DRKS00017036) because at the time when the study was designed the implications for clinicians were not as obvious as they are now. We (and colleagues such as Prof. Kaptchuk at Harvard Medical School) strongly believe that our study showing predisposing factors for nocebo responses in a very large sample is unique and extremely important for all clinicians. Further, we would like to point out that our study has been pre-approved by the local ethics committee with a detailed study protocol.Funding StatementThis study was financially supported by the European Research Council (grant ERC-2010-AdG_20100407). Bjoern Horing was supported by the Alexander von Humboldt Foundation. However, the funding agency had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee of the Medical Board Hamburg, Germany.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is stored at University Clinic Hamburg-Eppendorf.